Date:4/9/2012

sable Medical Supplies market research report published this month. US demand for disposable medical supplies is forecast to increase 4.3 percent annually to $46.7 billion in 2016, driven by an expanding volume of patient care activity spurred by aging demographic patterns, a rising incidence of diseases and disorders, and the extension of health insurance coverage by the Affordable Care Act of 2010. Demand will continue to build upward momentum as hospitals, outpatient facilities, and other health care establishments adopt more strict infection prevention safeguards. Health care cost containment pressures will remain the key moderating influence on growth in the US disposable medical supplies market, while hospitals and other medical providers become increasingly price sensitive as public and private health insurance concerns tighten restrictions on fees paid for patient procedures.

An Executive Summary of these trends and more and free sample of the full report are available at http://www.giiresearch.com/report/fd235745-disposable-medical-supplies-2016.html

Drug Delivery Systems to 2015

This new market research forecasts US drug delivery product demand to rise 7.4 percent yearly to reach $134 billion in 2015. Parenteral products will grow the fastest, led by monoclonal antibodies and polymer-encapsulated medicines. Other types expected to do well include prefilled dry powder and metered dose brachytherapy implants, and implantable drug delivery products.

This brand new market research study analyzes the $93.8 billion US drug delivery system industry, and presents historical demand data for the years 2000, 2005 and 2010, alongside forecasts for 2015 and 2020 by excipient (e.g., polymers, cellulose, minerals), product type (e.g., oral, parenteral, inhalation, implantable, transdermal) and application (e.g., central nervous system, res
'/>"/>

SOURCE Global Information Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
2. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
3. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
4. Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
5. Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens
6. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
7. Insmeds ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
8. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
9. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
10. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
11. Counting Calories Inadequate for Sustained Weight Loss